-

VFS Shareholders With Large Losses Should Contact Robbins LLP for Information About Their Rights Against VinFast Auto Ltd.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired VinFast Ltd. Inc. (NASDAQ: VFS) securities: (a) pursuant to the Offering Documents issued in connection with the August 14, 2023 merger among VinFast, Black Spade, and Nuevo Tech Ltd.; or (b) between August 15, 2023 and January 24, 2024. VinFast describes itself as “an innovative, full-scale mobility platform focused primarily on designing and manufacturing premium EVs (“electric vehicles”), e-scooters, and e-buses.”

For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.

The Allegations: Robbins LLP is Investigating the Allegations that VinFast Auto Ltd. (VFS) Made False Statements in its Offering Documents in Support of its Merger

According to the complaint, prior to the merger, VinFast operated as a SPAC. On August 14, 2023, VinFast consummated the merger, and on August 15, 2023, the Company began trading under the ticker symbols VFS and VFSWW.

Leading up to and following the merger, Vinfast touted the Company’s potential, indicating that it aimed to accomplish its long-term growth strategies by, in part, “continu[ing] growing [its] global footprint into areas where [it] expect[ed] high [electric vehicle (“EV”)] demand growth,” and stated that it expected “[d]eliveries of vehicles to be between 40,000 and 50,000 vehicles in FY2023.”

However, on January 18, 2024, VinFast announced its Q4 2023 deliveries, which was short of its previously stated target. In response, VinFast’s shares fell over 2%, to close at $5.64 per share, representing a total decline of 84.78% from the Company’s first post-merger closing stock price of $37.06 per share on August 15, 2023.

The plaintiff alleges that the Offering Documents and defendants failed to disclose that: (i) VinFast lacked sufficient capital to execute its purported growth strategy; (ii) VinFast would be unable to meet its 2023 delivery targets; (iii) accordingly, VinFast had overstated the strength of its business model and operational capabilities, as well as its post-Merger business and/or financial prospects; and (iv) as a result, the Offering Documents and Defendants’ public statements throughout the class period were materially false and misleading.

What Now: You may be eligible to participate in the class action against VinFast Auto Ltd. Shareholders who want to serve as lead plaintiff for the class must file their papers with the court by June 11, 2024. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

About Robbins LLP: Some law firms issuing releases about this matter do not actually litigate securities class actions; Robbins LLP does. A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. Since our inception, we have obtained over $1 billion for shareholders.

To be notified if a class action against VinFast Auto Ltd. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas, Jr.
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Robbins LLP

NASDAQ:VFS

Release Summary
Robbins LLP is Investigating Allegations that VinFast Auto Ltd. (VFS) Made False Statements in its Offering Documents in Support of its Merger
Release Versions
$Cashtags

Contacts

Aaron Dumas, Jr.
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Social Media Profiles
More News From Robbins LLP

Regencell Bioscience Holdings Limited Class Action Reminder - Robbins LLP Encourages RGC Investors to Contact the Firm for Information About Their Rights

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Regencell Bioscience Holdings Limited (NASDAQ: RGC) securities between October 28, 2024 and October 31, 2025. Regencell is a purported early-stage bioscience company focused on the research, development, and commercialization of traditional Chinese medicine (“TCM”) for the treatment of attention-deficit/hyperactivity disorder (“ADHD”) and autis...

POET Technologies Inc. Class Action Reminder - Robbins LLP Encourages POET Investors to Contact the Firm for Information About Their Rights

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired POET Technologies Inc. (NASDAQ: POET) securities between April 1, 2026 and 8:57 A.M. ET on April 27, 2026. POET Technologies describes itself as a "design and development company offering photonic integrated packaging solutions based on the POET Optical Interposer™, a novel platform that allows the seamless integration of electronic and photoni...

Immutep Limited Class Action Reminder - Robbins LLP Encourages IMMP Investors to Contact the Firm for Information About Their Rights

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP is Investigating Allegations that Immutep Limited (IMMP) Misled Investors Regarding the Viability and Efficacy of its Drug CandidateOn May 5, 2026, a class action was filed on behalf of all investors who purchased or otherwise acquired Immutep Limited American Depository Receipts (NASDAQ: IMMP) between March 24, 2025 and March 12, 2026. Immutep is an Australian-based biotechnology company focused on developing Lymphocyte Activation Gene-3 (LAG-3) related i...
Back to Newsroom